Goldman Sachs Group Inc. increased its holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 93.6% in the first quarter, now owning 741,329 shares valued at $2,787,000. Oppenheimer issued an ‘Outperform’ rating on OLMA after its collaboration with Pfizer, setting a price target of $22. With a potential upside of over 130%, OLMA is strategically positioned with key players in HR-positive breast cancer. OLMA, a California-based biopharmaceutical company, is focused on developing therapies for women’s cancers. While OLMA shows promise as an investment, some AI stocks may offer greater upside potential and less downside risk.

Read more at Yahoo Finance: Goldman Sachs Raises Stake in Olema Pharmaceuticals, Inc. (OLMA)